ArticleActas espanolas de psiquiatria2025
Impact of 16S rRNA on Intestinal Flora Alterations and Early Diagnosis in Early Alzheimer's Disease Patients.
Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plant Polysaccharides in Alzheimer's Disease: From Phytochemistry to Microbiota-Gut-Brain Axis Mechanisms-Resolving the Pharmacokinetic-Pharmacodynamic Paradox.Molecules (Basel, Switzerland) · 2026Review
- Microbiome alterations in Alzheimer's disease: A systematic review of current evidence and global perspectives.Journal of Alzheimer's disease reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's Disease (AD), a complex clinical condition, relies on neuropsychological assessments for early diagnosis. Recently, the gut-brain axis has been recognized as crucial in AD development, with dysbiosis in gut microbiota implicated in disease progression. Utilizing 16S rRNA analysis provides comprehensive monitoring of gut microbiota, potentially revealing biological markers for Early Alzheimer's Disease (EAD). Therefore, this study aimed to investigate the diagnostic impact of 16S ribosomal RNA (rRNA) on changes in intestinal flora among EAD patients.
methodsThis study analyzed stool samples from 50 AD patients and 50 healthy controls between June 2022 and June 2023. Based on the disease stage, patients were categorized into EAD (n = 14) and Late Alzheimer's Disease (LAD) groups (n = 36). The V3-V4 region was sequenced using 16S rRNA quantitative Polymerase Chain Reaction (qPCR) to compare the composition of gut microbiota and differences in abundance among the three experimental groups.
resultsThe abundance and diversity of gut microbiota significantly increased in EAD patients compared to the healthy control group. Furthermore, 39 genera showed considerable variations between EAD and LAD patients and healthy controls, with notable increases in the abundance of Bryantella, Gemmiger, Desulfovibrio, Collinsella, and Odoribacter among EAD patients. Additionally, significant differences were observed across the Desulfovibrioales and Verrucomicrobiales, which could help distinguish EAD patients (Area Under the Curve (AUC) range 0.854, 0.966, p < 0.05).
conclusion16S rRNA technology can be used to identify EAD patients, with the Desulfovibrioales and Verrucomicrobiales indicators serving as potential biological markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.